Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 9/20 | 0.55 |
| ▸ | CHRM4 | P08173 | 9/20 | 0.55 |
| ▸ | CHRM5 | P08912 | 9/20 | 0.55 |
| ▸ | CHRM1 | P11229 | 9/20 | 0.55 |
| ▸ | CHRM3 | P20309 | 9/20 | 0.55 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.53 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19308438 | 1.00 | CHRM2 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16409353 | 0.98 | CHRM2 (0.57) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16409291 | 0.96 | CHRM2 (0.51) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16409282 | 0.91 | CHRM2 (0.47) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL8040886 | 0.84 | GRIN1 (0.55) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL10875957 | 0.79 | GRIN1 (0.42) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16409436 | 0.78 | SLC6A3 (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL16409437 | 0.78 | CHRM2 (0.43) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL121601 | 0.76 | HSD11B1 (0.46) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL7837194 | 0.75 | CHRM2 (0.45) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117466786-A | Penehyclidine hydrochloride impurity and preparation method thereof | 湖南一格制药有限公司 | 2024-01-30 | — | — | CN | claimed |
| CN-116903608-A | Preparation method of penehyclidine | 远大生命科学(武汉)有限公司 | 2023-10-20 | — | — | CN | claimed |
| CN-116514800-A | Preparation method of penehyclidine hydrochloride | 湖南一格制药有限公司 | 2023-08-01 | — | — | CN | claimed |
| CN-111925281-B | Preparation method of penehyclidine hydrochloride impurity 2-cyclopentyl-2-phenylacetaldehyde | 江苏恩华药业股份有限公司 | 2022-04-15 | — | — | CN | claimed |
| CN-109851615-B | Process for purifying penehyclidine | 上海旭东海普药业有限公司 | 2021-06-08 | — | — | CN | claimed |
| CN-111925281-A | Preparation method of penehyclidine hydrochloride impurity 2-cyclopentyl-2-phenylacetaldehyde | 江苏恩华药业股份有限公司 | 2020-11-13 | — | — | CN | claimed |
| CN-110343036-A | A kind of preparation method of cyclopentyl phenyl acetaldehyde | 武汉大安制药有限公司 | 2019-10-18 | — | — | CN | claimed |
| CN-109851615-A | The method for purifying amyl ethyl quin ether | 上海旭东海普药业有限公司 | 2019-06-07 | — | — | CN | claimed |
| CN-109824661-A | The preparation method of impurity in a kind of amyl ethyl quin ether hydrochloride | 山东博洛德生物科技有限公司 | 2019-05-31 | — | — | CN | claimed |
| CN-104072345-B | A kind of method being applicable to prepare 1-cyclopentyl-2-methoxyl group-1-phenylethyl alcohol | CHENGDU LIST PHARMACEUTICAL RESEARCH CO., LTD. (CN) | 2016-06-01 | — | — | CN | claimed |
| CN-118619939-A | Synthesis method of penehyclidine hydrochloride | 国药集团工业有限公司廊坊分公司 | 2024-09-10 | — | — | CN | disclosed |
| CN-118480037-A | Preparation method of penehyclidine hydrochloride | 重庆先洋医药科技有限公司 | 2024-08-13 | — | — | CN | disclosed |
| CN-117466786-A | Penehyclidine hydrochloride impurity and preparation method thereof | 湖南一格制药有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-117466786-A | Penehyclidine hydrochloride impurity and preparation method thereof | 湖南一格制药有限公司 | 2024-01-30 | — | — | CN | disclosed |
| CN-116903608-A | Preparation method of penehyclidine | 远大生命科学(武汉)有限公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-1790643-B1 | QUINUCLIDINE COMPOUNDS HAVING QUATERNARY AMMONIUM GROUP, IT'S PREPARATION METHOD AND USE AS BLOCKING AGENTS OF ACETYCHOLINE | ZHAO SHUQIANG (CN) | 2010-06-02 | — | — | EP | disclosed |
| US-20090163541-A1 | QUINUCLIDINE COMPOUNDS HAVING QUATERNARY AMMONIUM GROUP, ITS PREPARATION METHOD AND USE AS BLOCKING AGENTS OF ACETYLCHOLINE | Zhao, Shuqiang (CN) | 2009-06-25 | — | — | US | disclosed |
| US-7521559-B2 | Quinuclidine compounds having quaternary ammonium group, its preparation method and use as blocking agents of acetylcholine | Zhao, Shuqiang (CN) | 2009-04-21 | — | — | US | disclosed |
| US-20080247963-A1 | Quinuclidine Compounds Having Quaternary Ammonium Group, Its Preparation Method and Use as Blocking Agents of Acetylcholine | Zhao, Shuqiang (CN) | 2008-10-09 | — | — | US | disclosed |
| EP-1790643-A1 | QUINUCLIDINE COMPOUNDS HAVING QUATERNARY AMMONIUM GROUP, IT'S PREPARATION METHOD AND USE AS BLOCKING AGENTS OF ACETYCHOLINE | Zhao, Shuqiang (CN) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080247963-A1 | Quinuclidine Compounds Having Quaternary Ammonium Group, Its Preparation Method and Use as Blocking Agents of Acetylcholine | CHRM1, CHRNA1, CHRM2 | CHRM2 3/4885CHRM4 14/4885CHRM5 8/4885 |
| US-20090163541-A1 | QUINUCLIDINE COMPOUNDS HAVING QUATERNARY AMMONIUM GROUP, ITS PREPARATION METHOD AND USE AS BLOCKING AGENTS OF ACETYLCHOLINE | CHRM1, CHRNA1, CHRNG | CHRM2 5/4885CHRM4 17/4885CHRM5 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.